Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in R/R Mantle Cell Lymphoma (SPARK)
NCT01599949Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2012
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in mantle cell lymphoma (MCL), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall Response Rate at 1 year. Started Aug 2012; status: completed.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01599949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01599949.